273 related articles for article (PubMed ID: 37437905)
1. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial.
Duan Y; Bai Y; Guo W; Wang L; Dai W; Guo W; Huang H; Liu W; Diao Z
Nephrol Dial Transplant; 2023 Dec; 39(1):95-102. PubMed ID: 37437905
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
Peng L; Wei SY; Li LT; He YX; Li B
J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial.
Choi JY; Kim DK; Kim YW; Yoo TH; Lee JP; Chung HC; Cho KH; An WS; Lee DH; Jung HY; Cho JH; Kim CD; Kim YL; Park SH
J Korean Med Sci; 2018 Feb; 33(9):e74. PubMed ID: 29441742
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Jul; 100(28):e26628. PubMed ID: 34260552
[TBL] [Abstract][Full Text] [Related]
6. Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.
Katsuno T; Ozaki T; Kim H; Kato N; Suzuki Y; Akiyama S; Ishimoto T; Kosugi T; Tsuboi N; Ito Y; Maruyama S
Intern Med; 2017; 56(13):1679-1686. PubMed ID: 28674357
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
8. [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome].
Geng HY; Ji LN; Chen CY; Tu J; Li HR; Bao R; Lin Y
Zhonghua Er Ke Za Zhi; 2018 Sep; 56(9):651-656. PubMed ID: 30180402
[No Abstract] [Full Text] [Related]
9. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy.
Cattran DC
Semin Nephrol; 2003 May; 23(3):272-7. PubMed ID: 12838495
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
12. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
Liu Z; Zhang H; Liu Z; Xing C; Fu P; Ni Z; Chen J; Lin H; Liu F; He Y; He Y; Miao L; Chen N; Li Y; Gu Y; Shi W; Hu W; Liu Z; Bao H; Zeng C; Zhou M
Ann Intern Med; 2015 Jan; 162(1):18-26. PubMed ID: 25383558
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population.
Lin S; Li HY; Zhou T; Lin W
Drug Des Devel Ther; 2019; 13():2305-2330. PubMed ID: 31371924
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate Mofetil with Steroid, a Reasonable Alternative to Current First-line Therapy, for Idiopathic Membranous Nephropathy in Resource-constrained Settings: A Randomized, Open-label Study.
Sharma M; Roy A; Doley PK; Pegu G
J Assoc Physicians India; 2024 Jun; 72(6):15-19. PubMed ID: 38881128
[TBL] [Abstract][Full Text] [Related]
16. [The clinical efficacy and safety of modified Ponticelli regimen for treatment of idiopathic membranous nephropathy].
Xia W; Pei H; Li S; Fu S; Tian L
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):181-5. PubMed ID: 26926368
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Dec; 100(51):e28225. PubMed ID: 34941086
[TBL] [Abstract][Full Text] [Related]
18. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Wong SC; Willis NS; Craig JC
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide.
Branten AJ; du Buf-Vereijken PW; Vervloet M; Wetzels JF
Am J Kidney Dis; 2007 Aug; 50(2):248-56. PubMed ID: 17660026
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
